Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Epigenomics AGFRA:ECX -0.53%18 Forward PE Ratio is 0.00 as of Jul. 18, 2026. GuruFocus rates FRA:ECX with a GF Score™ of 18/100 and a GF Value™ of €0.09 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 87 Medical Diagnostics & Research companies, Epigenomics AG ranks worse than 1149424.14% on this metric.
Epigenomics AG (FRA:ECX) Forward PE Ratio Explanation
The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.
Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .
Epigenomics AG Forward PE Ratio Related Terms
Epigenomics AG Forward PE Ratio Historical Data
* Premium members only.
The historical data trend for Epigenomics AG's Forward PE Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Epigenomics AG Forward PE Ratio Chart
Epigenomics AG Annual Data
Trend
Forward PE Ratio
Epigenomics AG Semi-Annual Data
Forward PE Ratio
FRA:ECX vs TMO, DHR, IDXX: Forward PE Ratio Comparison
For the Diagnostics & Research subindustry, Epigenomics AG's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Epigenomics AG Forward PE Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Epigenomics AG's Forward PE Ratio distribution charts can be found below:
* The bar in red indicates where Epigenomics AG's Forward PE Ratio falls into.
It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.
Epigenomics AG (FRA:ECX) has a Forward PE Ratio of 0.00 as of Jul. 18, 2026. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Epigenomics AG and its competitors. According to the industry distribution chart, Epigenomics AG ranks #999999 out of 87 companies in the Medical Diagnostics & Research industry.
Is Epigenomics AG's Forward PE Ratio too high?
Epigenomics AG's current Forward PE Ratio is 0.00. Based on the distribution chart, Epigenomics AG ranks #999999 out of 87 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Epigenomics AG has a GF Score™ of 18/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Epigenomics AG's Forward PE Ratio compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Epigenomics AG ranks #999999 out of 87 companies for Forward PE Ratio. This places Epigenomics AG in the lower half of its industry. The industry median Forward PE Ratio is 22.01. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward PE Ratio for a Medical Diagnostics & Research company?
The median Forward PE Ratio among Medical Diagnostics & Research companies is 22.01, based on 87 companies in the industry. Companies in the top quartile (top 25%) have a Forward PE Ratio significantly above this median, while those in the bottom quartile fall well below. However, Forward PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward PE Ratio mean?
A high Forward PE Ratio can signal that a stock is expensive relative to its fundamentals. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Epigenomics AG and its competitors. For the Medical Diagnostics & Research industry, the median Forward PE Ratio is 22.01 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Epigenomics AG's current Forward PE Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Epigenomics AG stock overvalued right now?
Based on GuruFocus' analysis, Epigenomics AG (FRA:ECX) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.09, compared to a current price of €0.94 — trading 944.4% above its estimated fair value. The current Forward PE Ratio is 0.00. Epigenomics AG's overall GF Score™ is 18/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward PE Ratio calculated?
Forward PE Ratio is calculated from a company's financial statements. For Epigenomics AG (FRA:ECX), the current Forward PE Ratio is 0.00 as of Jul. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Epigenomics AG (FRA:ECX) Overvalued in 2026?
Based on GuruFocus' analysis, Epigenomics AG stock appears to be overvalued.
The current stock price of €0.94 is trading 944.4% above its estimated GF Value™ of €0.09.
GuruFocus considers Epigenomics AG to be Significantly Overvalued.
Key valuation signals for FRA:ECX:
Forward PE Ratio: 0.00
GF Value™: €0.09 vs. price of €0.94 (944.4% above fair value)
No single metric tells the full story. See the FRA:ECX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Epigenomics AG is a molecular diagnostics company, that focuses on developing and commercializing in vitro diagnostic liquid biopsy tests for the screening, early detection, and diagnosis of cancer. The company develops and markets procedures and devices for the production in quantity of particular epigenetic parameters such as DNA methylation patterns as well as the information technology bases necessary for their procurement and evaluation. It is engaged in the development of novel molecular diagnostic products for cancer. The company products include Epi proColon, Epi BiSKit, HCCBloodTest, and Epi proLung. The company operates in Europe, Asia, and North America, majority of its revenue derives from Asia.
18GF Score
Get the complete analysis for FRA:ECX
Forward PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:ECX has been successfully added to your 
